Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBITDA Margin (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of EBITDA Margin data on record, last reported at 13275.0% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 718004.0% year-over-year to 13275.0%; the TTM value through Sep 2025 reached 9862.54%, down 526335.0%, while the annual FY2024 figure was 6055.35%, 264014.0% down from the prior year.
  • EBITDA Margin reached 13275.0% in Q3 2025 per NWBO's latest filing, up from 14645.8% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1473.18% in Q1 2023 and bottomed at 14645.8% in Q2 2025.
  • Average EBITDA Margin over 5 years is 6304.32%, with a median of 5667.2% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: skyrocketed 513965bps in 2022, then tumbled -1107012bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 2982.45% in 2021, then fell by -2bps to 3044.89% in 2022, then decreased by -12bps to 3402.7% in 2023, then tumbled by -223bps to 11006.06% in 2024, then decreased by -21bps to 13275.0% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 13275.0% in Q3 2025, 14645.8% in Q2 2025, and 5667.2% in Q1 2025.